Athersys is a late-stage biotechnology company developing their stem cell product MultiStem for multiple critical care indications. At present, they have two programs in late-stage development, ischemic stroke and acute respiratory distress syndrome ((ARDS)). Their partner in Japan, Healios, is also concurrently evaluating MultiStem for the same two indications. Additionally, they have multiple mid-stage and pre-clinical programs currently in development. Their product MultiStem, is an allogeneic, “off-the-shelf” cellular therapy derived from the bone marrow of healthy, consenting adults. MultiStem is highly scalable and can produce vast quantities of doses from a single donor bank. In